STOCK TITAN

Oncotelic Therapeutcs (OTLC) Stock News

OTLC OTC

Oncotelic Therapeutics, Inc. reports developments as a clinical-stage biopharmaceutical company focused on oncology, immunotherapy and rare-disease therapeutics. Company updates cover its internal drug pipeline, orphan oncology programs, antisense and small molecule injectable drug candidates, and partnerships or joint ventures used to license and co-develop selected candidates.

Recurring OTLC news also includes the PDAOAI AI platform for research, biomarker discovery, regulatory processes and GMP-compliant robotics, the company's 45% interest in GMP Bio and related Sapu Bio and Sapu Nano programs, and completed portfolio actions such as field-specific monetization of N2B nose-to-brain delivery assets.

Rhea-AI Summary

Oncotelic Therapeutics (OTLC) announced a peer-reviewed liver cancer study identifying a four-gene prognostic signature to guide patient stratification in Sapu003 trials. Published in Biomedicines on October 23, 2026, the study combined PDAOAI-guided literature investigation with gene-expression and survival analyses in hepatocellular carcinoma, a form of liver cancer.

The signature comprises FKBP1A, EIF4E, RRAGC and PPARGC1A. Its association with survival was independently validated in a Japanese cohort of 203 patients. The findings define patient stratification for clinical trials of Sapu003, an intravenous formulation of everolimus; they are not a reported treatment result. Oncotelic said the analyses support advancing the findings into clinical development. Separately, the company plans to expand PDAOAI toward approximately 100 billion biological vectors for genetic and protein research.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.55%
Tags
none
-
Rhea-AI Summary

Oncotelic Therapeutics (OTLC) announced that Chief Business Officer Saran Saund will deliver a drug-discovery summit keynote on October 22, 2026.

The presentation at the 22nd Drug Discovery Strategic Summit will examine partition and aggregation: splitting complex research questions into focused investigations and combining their findings into testable hypotheses. Saund will connect this approach with PDAOAI technology, the company's international intellectual-property strategy and plans for 100 billion biological vectors. The keynote will also cover individual researcher access through Fastbot/Membot and a planned expansion into genetic discovery.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.86%
Tags
AI
-
Rhea-AI Summary

Oncotelic Therapeutics (OTLC) opened BIO REBOOT registration through its PDAOAI drug discovery platform, inviting scientists, AI developers and biotech founders to collaborate. Registration is free. Selected projects may be considered for startup funding and support with validation, formulation, regulatory planning and clinical development. Funding, platform access and development support depend on scientific review, available resources and agreed terms.

Saran Saund and Scott Myers will deliver keynote presentations at Drug Discovery 2026, held October 7–9 in Burlingame, California. The presentations cover biomedical literature search and a liver cancer case study identifying a candidate four-gene signature for further research. PDAOAI’s Partitioned Literature Aggregation method analyzes disease-specific literature groups separately before combining findings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.33%
Tags
none
Rhea-AI Summary

Oncotelic Therapeutics (OTCQB: OTLC) and Sapu Nano announced a peer-reviewed Biomedicines publication detailing the preclinical translational package for Sapu003, an intravenous Deciparticle™ formulation of everolimus. The study covers ADME, pharmacokinetics, tissue distribution, metabolism, excretion, GLP repeat-dose toxicology, cGMP manufacturing, release testing, and product stability.

The data show Deciparticle™ technology enabled a clinically manufacturable IV everolimus while maintaining intrinsic metabolic characteristics and reducing gastrointestinal exposure versus oral everolimus, with no treatment-related gastric pathology in GLP studies. According to Oncotelic, the work supports the ongoing Phase 1b trial SP-03-B101 in advanced mTOR-sensitive solid tumors and demonstrates reproducible cGMP manufacturing, which the company views as strong validation of the Deciparticle™ platform.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.76%
Tags
-
Rhea-AI Summary

Oncotelic (OTCQB:OTLC)/b) and its 45%-owned subsidiary Sapu Nano completed the initial safety cohort of the Phase 1b trial of Sapu003, an intravenous everolimus formulation. The Safety Review Committee observed no dose-limiting toxicities and recommended escalation to the next dose level.

The company has begun expanding the trial into Europe to add sites and accelerate enrollment. A recent peer-reviewed publication details the Deciparticle™ nanoparticle platform, highlighting scalable cGMP manufacturing, stability, compatibility with multiple hydrophobic drugs, and preclinical antitumor activity supporting Sapu003’s clinical development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.49%
Tags
none
-
Rhea-AI Summary

Oncotelic (OTCQB: OTLC) and Sapu Nano reported peer-reviewed validation of their Deciparticle™ nanoparticle platform through development of Sapu003, an intravenous everolimus formulation.

The International Journal of Molecular Sciences paper describes formulation design, scalable cGMP manufacturing, stability, preclinical antitumor activity, and supports the ongoing Phase 1b trial in advanced mTOR-sensitive solid tumors with weekly IV Sapu003 plus exemestane.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.92%
Tags
Rhea-AI Summary

Oncotelic (OTCQB: OTLC) launched an AI-powered GMP manufacturing services platform at BIO International Convention 2026 in San Diego. The Platform combines the PDAOAI™ AI system, digital batch records, and intelligent robotics via a collaboration with TechForce Robotics to support modern pharmaceutical manufacturing.

The Platform targets pharma, biotech, CDMOs, and advanced therapy developers by enabling electronic batch records, GMP workflow digitization, quality support, process monitoring, and robotic integration. Oncotelic is also showcasing its Deciparticle™ nanomedicine platform, including SAPU003 in a Phase 1b clinical study.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.78%
Tags
AI
-
Rhea-AI Summary

Oncotelic Therapeutics (OTCQB: OTLC) announced completion of key Phase 2 objectives in its AI-powered GMP manufacturing automation initiative with TechForce Robotics at SAPU Bio, its 45%-owned OEB-5 sterile injectable cGMP joint venture.

The PDAOAI™ platform now supports sterile operations, eBR, GMP workflows, cleanroom monitoring, and autonomous materials movement, and will be showcased at BIO International Convention 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.49%
Tags
AI
-
Rhea-AI Summary

Oncotelic (OTC:OTLC) will showcase its PDAOAI™ drug discovery platform in the Product & Engineering keynote at Qdrant Vector Space Day 2026 on June 11 in San Francisco.

According to Oncotelic, PDAOAI indexes about 28 million PubMed abstracts on Qdrant and incorporates novel manifold folding and shell sampling techniques to enhance biomedical knowledge retrieval and reduce LLM hallucinations.

The company reports compressing development of SAPU 003 and SAPU 006 from concept to IND within 24 months, including GMP manufacturing build-out and first-in-human clinical material shipment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.26%
Tags
none
Rhea-AI Summary

Oncotelic Therapeutics (OTCQB: OTLC) was featured in a BioMedWire editorial highlighting nanotechnology-based oncology drug delivery. The company is developing Sapu003 and its Deciparticle platform, focusing on nanotech-driven delivery systems and pharmacokinetic optimization to enhance existing cancer therapies rather than discovering entirely new compounds.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.00%
Tags
none

FAQ

What is the current stock price of Oncotelic Therapeutcs (OTLC)?

Oncotelic Therapeutcs (OTLC) last closed at $0.0125.

What is the market cap of Oncotelic Therapeutcs (OTLC)?

The market cap of Oncotelic Therapeutcs (OTLC) is approximately $5.7M.